News Archive
January 2010
FX125L Phase I complete
Funxional Therapeutics announced on 8th January that they have successfully complete Phase I development of our lead BSCI, FX125L. The compound was well tolerated at all doses tested, including the highest dose, 1500mg daily for 10 days.
November 2009
When Worlds Collide
Recent advances in both autoimmunity and atherosclerosis research increasingly highlight common mechanisms between the two disease areas. In a November editorial, we discuss the implications.
January 2010
Valuing Ideas
Once upon a time, a good idea was worth a million pounds. Today, with ideas ten a penny, how can inventors of early stage technologies hope to earn a living? David Grainger explores the issues in his recent blog post.
November 2009
Virtual Biotech
To be or not to be - that is the most pressing question for biotech companies today. In his recent blog article, David Grainger asks just how much out-sourcing is the right amount?
November 2009
Clinical Results Presented
Further details of the clinical experience with our lead BSCI, FX125L, was presented at the November meeting of the American College of Asthma, Allergy and Inflammation meeting in Miami, FL, USA.
July 2009
Harder Times for Biotech?
It's easy to think that the credit crunch is the only bad news for the biotech industry. But in a recent blog post, David Grainger explains why he thinks the problems run deeper than that. A radical change of approach may be needed.
July 2009
New BSCIs Published
Our latest research has been published in the Journal of Medicinal Chemistry. Continuing optimization has now yielded a range of orally bioavailable Broad-spectrum Chemokine Inhibitors.
July 2009
FX125L Phase I Results
Funxional Therapeutics announced on 8th July 2009 that they have successfully complete the first Phase I clinical trial of FX125L in healthy volunteers. FX125L is our lead Broad-spectrum Chemokine Inhibitor, and this is the first experience with this new class of anti-inflammatory agents in man.
November 2008
Major expansion of BSCI Research
Our research into the mechanism of action of Broad-spectrum chemokine inhibitors (BSCIs) has received a major boost, with the announcement that local biotechnology company Funxional Therapeutics Ltd are to expand their collaboration with Cambridge University.
January 2008
Anna Kauppi awarded Fellowship to join Lab
Anna Kauppi, from the University of Umea, Sweden, has been awarded a Fellowship from the Wenner-Gren Foundation to join the lab from 5th February 2008. Anna will join the cadUK project, using multivariate modelling to evaluate different diagnostic paradigms from coronary heart disease.
January 2007
9th Annual Summer Studentships
The competition for the Eighth Annual Poniard / Cambridge University Biomedical Summer Studentships for 2008 is now open. The closing date for applications is 15th February 2008
January 2007
Funxional Therapeutics support BSCI research
Following the successful sub-licensing of our BSCI technology platform from the french pharmaceutical company Ipsen to a newly formed Cambridge biotechnology company, Funxional Therapeutics (FXT), in October of 2006, FXT have today announced their continued support for our BSCI research programme.
November 2003
Translational Research Unit opens at Papworth
The newly-formed Translational Research Unit, under the direction of Dr David Grainger, opened its doors in temporary accomodation at Papworth Hospital NHS Trust on 10th November 2003